Article originalHépatite chronique C : gestion des effets indésirables du traitementChronic hepatitis C: management of side effects of treatment
Références (73)
- et al.
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
Lancet
(2001) - et al.
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
J Hepatol
(2006) - et al.
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels
Gastroenterology
(2004) - et al.
Adherence to combination therapy enhances sustained response in genotype-1 infected patients with chronic hepatitis C
Gastroenterology
(2002) - et al.
Side effects of therapy for chronic hepatitis C
Gastroenterology
(2003) Y a-t-il un risque à prescrire du paracétamol chez les malades atteints d’hépatopathies aiguës ou chroniques ?
Gastroenterol Clin Biol
(2006)Hepatitis C virus infection: quality of life and side effects of treatment
J Hepatol
(1999)- et al.
Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alpha therapy
Hepatology
(1997) - et al.
Randomized trial if interferon-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group
Lancet
(1998) - et al.
A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-alpha
Am J Gastroenterol
(2001)
Gastroenterology
(2004)
Rapid suppression of hematopoiesis by standard or pegylated interferon alfa
Gastroenterology
(2002)
Randomized controlled trial of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of chronic hepatitis C
Cytokine
(2000)
Inhibition of theophylline metabolism by interferon
Lancet
(1987)
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
N Engl J Med
(2002)
Peginterferon-alpha-2a and ribavirin combination therapy in chronic hepatitis C: randomized study of treatment duration and ribavirin dose
Ann lntern Med
(2004)
What is the optimal treatment for naïve patients with chronic hepatitis C?
Le virus de l’hépatite C de génotype 4 : caractéristiques épidémiologiques et réponse aux traitements antiviraux
Gastroenterol Clin Biol
(2003)
Peginterferon alpha-2a and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response
Gut
(2005)
Effectiveness of interferon plus ribavirin combination in the treatment of naive patients wlth hepatitis C virus type 5. A French multicentre retrospective study
Aliment Pharmacol Ther
(2006)
Traitement de l’hépatite C
(2004)
Hépatite chronique C : quelles sont les recommandations en dehors du traitement antiviral ?
Gastroenterol Clin Biol
(2002)
Steatosis and HCV: dangerous liaisons
Alcohol in chronic hepatitis C: legal or prohibited
Effets secondaires de l’interferon alpha
Gastroenterol Clin Biol
(1996)
Suivi de l’hépatite chronique C traitée
Gastroenterol Clin Biol
(1997)
Traitement de l’hépatite chronique C : effets secondaires, tolérance et qualité de vie
Gastroenterol Clin Biol
(2002)
Side-effects of therapy of hepatitis C and their management
Hepatology
(2002)
A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue
Hepatology
(2005)
Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomized, double blind, placebo controlled study
Gut
(2005)
Hepatitis C, interferon alfa, and depression
Hepatology
(2000)
Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions
J Clin Oncol
(2000)
Hépavir, première étude observationnelle d’une cohorte de malades traités par interféron alpha-2a en monothérapie. Évaluation de l’asthénie et de ses répercussions socials
Gastroenterol Clin Biol
(2001)
Mesure de la qualité de vie chez les malades ayant une hépatite chronique virale C : validation d’un indicateur général et d’un indicateur spécifique
Gastroenterol Clin Biol
(1999)
An open-label trial of citalopram for major depression in patients with hepatitis C
J Clin Psychiatry
(2002)
Cited by (10)
Treatment of chronic hepatitis C: The latest therapeutic advances
2013, Pharmacien Hospitalier et ClinicienHypersensitivity to new therapy for hepatitis C infection
2013, Revue Francaise d'AllergologieEducation by a Nurse Increases Response of Patients With Chronic Hepatitis C to Therapy With Peginterferon-α2a and Ribavirin
2011, Clinical Gastroenterology and HepatologyHepatitis C intervention research - Where are we now and where should we be heading?
2009, Arab Journal of GastroenterologyIs physical activity possible and beneficial for patients with hepatitis C receiving pegylated interferon and ribavarin therapy?
2009, Gastroenterologie Clinique et BiologiqueManagement of chronic hepatitis C in 2008
2008, Gastroenterologie Clinique et Biologique
Copyright © 2007 Elsevier Masson SAS. All rights reserved.